

ZEPOSIA IS THE ONLY ORAL ADVANCED THERAPY^a FOR UC THAT CAN BE USED ACROSS ALL MODERATE-TO-SEVERE LINES OF THERAPY¹⁻³

WHEN BIOLOGICS NO LONGER PROVIDE RELIEF

PATIENT NAME: JORGE

- Age: 54
- Diagnosis: moderately to severely active UC
- Sex: male
- Time since diagnosis: 25 years



Not an actual patient.

BACKGROUND

• Jorge is a 54-year-old male with a demanding work life as a long-haul truck driver. He has struggled with ulcerative colitis since receiving his diagnosis in 1997. At first, he found relief with biologic treatment. Jorge has tried other treatments over time and his current one no longer provides relief. He relies on rest stops when he's on the road but with his symptoms worsening, it's becoming a struggle. Additionally, infusion treatments just don't work with his busy schedule

SYMPTOMS

- Increased stool frequency (3-4 more stools per day than normal)
- Rectal bleeding

MEDICATIONS

5-ASAs, corticosteroids to control flares; previously discontinued TNFi due to a loss of response

ASSESSMENT

- Vitals: within limits of normal
- Comorbidities: none
- Extent of disease: pancolitis

• Endoscopic evaluation: marked erythema, absent vascular pattern, friability, granularity, spontaneous bleeding, and ulcerations

REASON FOR MOST RECENT VISIT

To discuss treatment options—he is concerned about his worsening symptoms and wants a treatment option that can provide relief while fitting into his busy work life

ADDITIONAL CONSIDERATIONS

- Travels extensively on an irregular schedule
- Open to new therapy options

Clinical Trial: the efficacy and safety of ZEPOSIA were evaluated in 2 multicenter, randomized, double-blind, placebo-controlled clinical studies (UC Study 1 [induction] and UC Study 2 [maintenance]) in adult patients with moderately to severely active ulcerative colitis, defined as a Mayo score of 6 to 12 at baseline.¹ Primary Endpoint of Clinical Remission Is Defined as: rectal bleeding subscore (RBS)=0, stool frequency subscore (SFS) 0 or 1 (and a decrease of ≥1 point from baseline SFS), and endoscopy subscore 0 or 1 without friability.¹

<u>UC Study 1 (0-week induction)</u>: 645 patients were randomized 2:1 to either ZEPOSIA 0.92 mg given orally once daily or placebo for 10 weeks, beginning with a dosage titration. The trial included patients who had an inadequate response or were intolerant to any of the following: oral aminosalicylates, corticosteroids, immunomodulators, or a biologic. Patients were required to be on stable doses of oral aminosalicylates and/or corticosteroids.¹

UC Study 2 (42-week maintenance): 457 patients who received ZEPOSIA in either UC Study 1 or in an open-label arm and achieved clinical response at Week 10 were re-randomized 1:1 and were treated with either ZEPOSIA 0.92 mg (n=230) or placebo (n=227) for 42 weeks (UC Study 2), for a total of 52 weeks of treatment.

^aAdvanced therapies include S1P, biologics, and JAKi. 5-ASAs=5-aminosalicylic acids; JAKi=Janus kinase inhibitor; S1P=sphingosine 1-phosphate; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis.

INDICATION

ZEPOSIA® (ozanimod) is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

IMPORTANT SAFETY INFORMATION

Contraindications:

• Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker

Please see additional Important Safety Information throughout and the full <u>Prescribing Information</u> and <u>Medication Guide</u>.

ZEPOSIA IS THE ONLY ORAL ADVANCED THERAPY^a FOR UC THAT CAN BE USED ACROSS ALL MODERATE-TO-SEVERE LINES OF THERAPY¹⁻³

Proven Control With ZEPOSIA—Rapid and Sustained Clinical Remission and Clinical Response at Weeks 10 and 52¹



Not an actual patient.

^aAdvanced therapies include S1P, biologics, and JAKi.

*Clinical remission is defined as: rectal bleeding subscore (RBS)=0, stool frequency subscore (SFS) 0 or 1 (and a decrease of ≥1 point from baseline SFS), and endoscopy subscore 0 or 1 without friability.

Clinical response is defined as a reduction from baseline in the 3-component Mayo score of ≥2 points and ≥35%, and a reduction from baseline in the rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1.¹

Disease Control in TNFi-exposed Patients Observed at Weeks 10 and 52¹



^aEfficacy analysis by prior TNFi therapy was prespecified, but not powered to detect a difference in the treatment effect in these subgroups.⁴ ^bClinical remission is defined as: rectal bleeding subscore (RBS)=0, stool frequency subscore (SFS) 0 or 1 (and a decrease of ≥1 point from baseline SFS), and endoscopy subscore 0 or 1 without friability.¹

 \mathbb{C} Clinical response is defined as a reduction from baseline in the 3-component Mayo score of ≥ 2 points and $\ge 35\%$, and a reduction from baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

IMPORTANT SAFETY INFORMATION (cont'd) Contraindications (cont'd)

- Patients with severe untreated sleep apnea
- Patients taking a monoamine oxidase (MAO) inhibitor

Infections: ZEPOSIA may increase the susceptibility to infections. Life-threatening and rare fatal infections have occurred in patients receiving ZEPOSIA. Obtain a recent (i.e., within 6 months or after discontinuation of prior UC therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA. Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection. Continue monitoring for infections up to 3 months after discontinuing ZEPOSIA.

Please see additional Important Safety Information throughout and the full <u>Prescribing Information</u> and <u>Medication Guide</u>.

A DEMONSTRATED SAFETY PROFILE

Adverse Reactions With an Incidence of at Least 2% in ZEPOSIA-Treated Patients and at Least 1% Greater Than Placebo in Patients With UC¹

Induction Periods (UC Study 1 and Study 3ª)			
Adverse Reaction	ZEPOSIA 0.92 mg (n=496) ^{d,e}	Placebo (n=281)°	
Upper Respiratory Infection ^b	5%	4%	
Liver Test Increased ^c	5%	0%	
Headache	4%	3%	
Pyrexia	3%	2%	
Nausea	3%	2%	
Arthralgia	3%	1%	

^aAdditional data from the induction period of a randomized, double-blind, placebo-controlled study [TOUCHSTONE, or, UC Study 3] included 67 patients who received ZEPOSIA 0.92 mg once daily.¹

Includes or patients who received 22POSIA of 0.92 mg once daily.
Includes the following terms: streptococcal pharyngitis, pharyngotonsillitis, bacterial pharyngitis, nasopharyngitis, upper respiratory tract infection, pharyngitis, sinusitis, tonsillitis, viral upper respiratory tract infection, laryngitis, sacute sinusitis, catarrh, chronic sinusitis, upper respiratory tract infection, chronic tonsillitis, viral pharyngitis, viral sinusitis, bacterial sinusitis, bacterial upper respiratory tract infection, viral labyrinthitis, laryngeal inflammation.
Includes the following terms: gamma-glutamyl transferase increased, alanine aminotransferase increased, aspartate aminotransferase increased.

^cIncludes the following terms: gamma-glutamyl transferase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, hyperbilirubinemia, liver function test increased, blood alkaline phosphatase increased, and transaminases increased.¹ ^dZEPOSIA was initiated with a 7-day titration.¹

^ePercentages were calculated as the sum of each individual study percentage multiplied by its Cochran-Mantel-Haenszel weight.¹

Adverse Reactions With an Incidence of at Least 4% in ZEPOSIA-Treated Patients and at Least 1% Greater Than Placebo in Patients With UC¹

Maintenance (UC Study 2)			
Adverse Reaction	ZEPOSIA 0.92 mg (n=230)	Placebo (n=227)	
Liver Test Increased ^a	11%	2%	
Headache	5%	<1%	

^aIncludes the following terms: gamma-glutamyl transferase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, hyperbilirubinemia, blood bilirubin increased, liver function test increased, blood alkaline phosphatase increased.¹

In patients treated with ZEPOSIA, rates of thromboembolic events (PE, venous and arterial thrombosis) or major adverse cardiac events (CV death, MI, stroke) were similar to patients treated with placebo in TRUE NORTH.^{5a}

^aIn the TRUE NORTH phase 3 studies, 1 case of ischemic stroke (0.2%) was reported in ZEPOSIA-treated patients versus no reports in patients treated with placebo.⁵

CV=cardiovascular; MI=myocardial infarction; PE=pulmonary embolism.

IMPORTANT SAFETY INFORMATION (cont'd)

Infections (cont'd)

- Herpes zoster was reported as an adverse reaction in ZEPOSIA-treated patients. Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating ZEPOSIA. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIA.
- Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another SIP receptor modulator. If CM is suspected, ZEPOSIA should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.
- In the UC clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of UC. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk



IMPORTANT SAFETY INFORMATION (cont'd) Infections (cont'd)

- of immunosuppression. When switching to ZEPOSIA from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects.
- Use of live attenuated vaccines should be avoided during and for 3 months after treatment with ZEPOSIA. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIA.

Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability. PML has been reported in patients treated with SIP receptor modulators, including ZEPOSIA, and other UC therapies and has been associated with some risk factors. If PML is suspected, withhold ZEPOSIA and perform an appropriate diagnostic evaluation.

If confirmed, treatment with ZEPOSIA should be discontinued.

Immune reconstitution inflammatory syndrome (IRIS) has been reported in MS patients treated with SIP receptor modulators who developed PML and subsequently discontinued treatment. IRIS presents as a clinical decline in the patient's condition that may be rapid, can lead to serious neurological complications or death, and is often associated with characteristic changes on MRI. The time to onset of IRIS in patients with PML was generally within a few months after SIP receptor modulator discontinuation. Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken.

Bradyarrhythmia and Atrioventricular Conduction Delays: Since initiation of ZEPOSIA may result in a transient decrease in heart rate and atrioventricular conduction delays, dose titration is recommended to help reduce cardiac effects. Initiation of ZEPOSIA without dose escalation may result in greater decreases in heart rate. If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought for those individuals:

- with significant QT prolongation
- with arrhythmias requiring treatment with Class la or III anti-arrhythmic drugs
- with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, and uncontrolled hypertension
- with a history of Mobitz type II second-degree or higher AV block, sick sinus syndrome, or sino-atrial heart block

Liver Injury: Elevations of aminotransferases may occur in patients receiving ZEPOSIA. Obtain liver function tests, if not recently available (i.e., within 6 months), before initiation of ZEPOSIA. Patients who develop symptoms suggestive of hepatic dysfunction should have hepatic enzymes checked and ZEPOSIA should be discontinued if significant liver injury is confirmed.

Fetal Risk: There are no adequate and well-controlled studies in pregnant women. Based on animal studies, ZEPOSIA may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 3 months after stopping ZEPOSIA.

Increased Blood Pressure: Increase in systolic pressure was observed after about 3 months of treatment and persisted throughout treatment. Blood pressure should be monitored during treatment and managed appropriately. Certain foods that may contain very high amounts of tyramine could cause severe hypertension in patients taking ZEPOSIA. Patients should be advised to avoid foods containing a very large amount of tyramine while taking ZEPOSIA. **Respiratory Effects:** ZEPOSIA may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy, if clinically indicated.

Macular Edema: SIP modulators have been associated with an increased risk of macular edema. Patients with a history of uveitis or diabetes mellitus are at increased risk. Patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation and regular follow-up examinations. An ophthalmic evaluation is recommended in all patients at any time if there is a change in vision. Continued use of ZEPOSIA in patients with macular edema has not been evaluated; potential benefits and risks for the individual patient should be considered if deciding whether ZEPOSIA should be discontinued.

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported in patients receiving a SIP receptor modulator. If a ZEPOSIA-treated patient develops unexpected neurological or psychiatric symptoms or any symptom/sign suggestive of an increase in intracranial pressure, a complete physical and neurological examination should be conducted. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, treatment with ZEPOSIA should be discontinued.

Unintended Additive Immunosuppressive Effects From Prior Immunosuppressive or Immune-Modulating Drugs: When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation. Initiating treatment with ZEPOSIA after treatment with alemtuzumab is not recommended.

Immune System Effects After Stopping ZEPOSIA: After discontinuing ZEPOSIA, the median time for lymphocyte counts to return to the normal range was 30 days with approximately 90% of patients in the normal range within 3 months. Use of immunosuppressants within this period may lead to an additive effect on the immune system, therefore caution should be applied when initiating other drugs 4 weeks after the last dose of ZEPOSIA.

Most Common Adverse Reactions (≥4%): liver test increased, upper respiratory infection, and headache. Use in Specific Populations: Hepatic Impairment: Dosage adjustment in patients with mild or moderate hepatic impairment (Child-Pugh class A or B) is required, and use of ZEPOSIA in patients with severe hepatic impairment (Child-Pugh class C) is not recommended.

Please see additional Important Safety Information throughout and the full <u>Prescribing Information</u> and <u>Medication Guide</u>.

References: 1. ZEPOSIA. Prescribing Information, Celgene Corporation, a Bristol Myers Squibb company; 2023. 2. Rinvoq [package insert]. North Chicago, Illinois: AbbVie Biotechnology Ltd; 2023. 3. Xeljanz [package insert]. New York, New York: Pfizer Inc; 2022. 4. Sandborn WJ, Feagan BG, D'Haens G, et al; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis [supplementary appendix]. N Engl J Med. 2021;385:1280-1291. 5. Long M, Cross RK, Lichtenstein GR, et al. Long-term cardiac safety of ozanimod in phase 3 clinical program of ulcerative colitis and relapsing multiple sclerosis. Presented at: Digestive Disease Week (DDW); San Diego, CA, and Virtual, May 21–24, 2022. Presentation 15.



Bristol Myers Squibb is committed to transparency. For information on the list price of ZEPOSIA as well as information regarding average out-of-pocket costs and assistance programs, please visit our pricing information page at ZEPOSIA.com/ulcerative-colitis/cost.

ZEPOSIA and ZEPOSIA logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company. All other trademarks are the property of their respective owners. © 2023 Bristol-Myers Squibb Company. Printed in the USA. 2084-US-2301250 10/23